Moleculin completes dosing of 90 patients in Part A of pivotal AML trial MIRACLE
Part A data for Annamycin plus cytarabine in relapsed or refractory AML are expected in the first quarter of 2027 and will guide dose selection for Part B.
Moleculin Biotech has said that all 90 patients enrolled in Part A of its Phase 2/3 MIRACLE trial have completed treatment. The study is testing Annamycin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukaemia (AML). The update came with the company's third-quarter 2026 results, published on 16 November 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Moleculin Biotech, Inc. ↗
Article written by VigiEye from the official source (Moleculin Biotech, Inc.). Claims are the company's own. AI-assisted; check the source before acting.